Girish Aakalu - Mar 15, 2022 Form 4 Insider Report for GENOCEA BIOSCIENCES, INC. (GNCA)

Role
CHIEF BUSINESS OFFICER
Signature
/s/ Diantha Duvall, Attorney-in-Fact for Girish Aakalu
Stock symbol
GNCA
Transactions as of
Mar 15, 2022
Transactions value $
-$2,637
Form type
4
Date filed
3/17/2022, 04:04 PM
Previous filing
Mar 16, 2022
Next filing
Apr 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GNCA Common Stock Award $0 +31.3K +67.1% $0.00 77.8K Mar 15, 2022 Direct F1
transaction GNCA Common Stock Sale -$2.64K -2.4K -3.08% $1.10 75.4K Mar 16, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GNCA Stock Option (Right to Buy) Award $0 +93.8K $0.00 93.8K Mar 15, 2022 Common Stock 93.8K $1.11 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units that represent the contingent right to receive, at settlement, one share of common stock. The restricted stock units are scheduled to vest 25% on each of the first four anniversaries of the grant date.
F2 Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person.
F3 The options are scheduled to vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date.